ACT Genomics Upgrades Clinically Recognized Genomic Test to 101-Gene Panel with 7-Day Turnaround

The upgraded ACTDrug® series is designed todeliver timely, actionable genomic insights at the time of diagnosis andinitial treatment planning, when early treatment decisions can significantlyimpact patient outcomes. With broader gene coverage and faster reporting,clinicians can more efficiently identify relevant biomarkers and considerappropriate targeted or immunotherapy options earlier in the treatment pathway.

Backed by nearly a decade of real-worldclinical use, ACTDrug® has supported more than ten thousand clinical casesacross major medical centers in Taiwan and Asia. The service has beenrecognized by clinicians for its clinical relevance, and practical value inguiding treatment selection.

The expanded 101-gene panel includesbiomarkers associated with:

• Targeted therapies
• Immunotherapy response
• Drug resistance mechanisms
• Emerging treatment strategies

In addition to the comprehensive ACTDrug®panel, ACT Genomics offers disease-specific subpanels for breast, lung, andgastrointestinal cancers. These targeted panels, ACTDrug® Breast, ACTLung^TM,and ACTDrug® GI, are designed with gene content aligned to current treatmentguidelines, enabling faster turnaround times and providing clinicians with anaccessible and practical tool for identifying clinically actionable biomarkers.

ACTDrug® continues to integrate ACT Genomics’proprietary bioinformatics pipelines and curated clinical knowledge bases,delivering physician-friendly reports that translate complex genomic data intoclear, actionable insights for routine clinical practice. With this globalrelease, ACT Genomics reinforces its commitment to advancing precision oncologyby providing reliable, timely, and clinically meaningful genomic testing tosupport cancer care worldwide.

‍

Availability Disclaimer

ACTDrug® testing services may not beavailable in all countries or regions. Service availability may vary dependingon local regulatory requirements and laboratory service arrangements.Healthcare professionals should consult ACT Genomics or local authorizedpartners for information regarding availability in their region.

‍

About ACT Genomics

ACT Genomics is a member of the Delta group.Specializing in genomic testing and bioinformatics solutions for oncology. Byintegrating next-generation sequencing (NGS), curated clinical databases, andexpertise in tumor biology, ACT Genomics delivers actionable insights tosupport treatment selection, disease monitoring, and clinical decision-makingin cancer care. Please visit the website for more information: https://www.actgenomics.com/

‍